Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants [Phase 3]

View source ↗

Summary

Phase 3 trial assessing rivaroxaban for VTE prophylaxis in ambulatory cancer patients has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2019-09-12